Evidence map›Paper›PMID 40180788›Full record

ArticleInfectious diseases and therapy2025

West Nile Virus Outbreak in Israel 2024 Compared with Previous Seasons: A Retrospective Study.

Guy Katzenellenbogen, Michal Canetti, Ili Margalit, Yonatan Shusterman, Alon Simchovitz-Gesher, Lior Naveh, Nadav Baharav, Miki Goldenfeld, Ana Belkin, Marina Brod and 14 more

Erratum issued Registry-linked trialAbstract read
In one paragraph

Article in Infectious diseases and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07094724 (High-titer West Nile Virus-neutralizing Plasma for Hospitalized Patients With West Nile Fever), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07094724 phase2recruitingnot on this map

High-titer West Nile Virus-neutralizing Plasma for Hospitalized Patients With West Nile Fever: a Prospective Controlled Clinical Study Using Historical Controls

TypeinterventionalSponsorGili Regev-Yochay MDRan2025 to 2025Enrolled37ConditionsWest Nile FeverArmsPlasma
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Guy Katzenellenbogen *Pediatric Infectious Diseases Unit, Safra Medical Center, Ramat-Gan, Israel.
Michal Canetti *Faculty of Medical and Health Sciences, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel. michalcanetti@gmail.com.ORCID http://orcid.org/0000-0001-5235-3447
Ili MargalitFaculty of Medical and Health Sciences, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel.
Yonatan ShustermanDepartment of Neurology, Sheba Medical Center, Ramat-Gan, Israel.
Alon Simchovitz-GesherInternal Medicine T, Sheba Medical Center, Ramat-Gan, Israel.
Lior NavehInfectious Diseases Unit, Sheba Medical Center, Ramat-Gan, Israel.
Nadav BaharavInfectious Diseases Unit, Sheba Medical Center, Ramat-Gan, Israel.
Miki GoldenfeldFaculty of Medical and Health Sciences, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel.
Ana BelkinInternal Medicine D, Sheba Medical Center, Ramat-Gan, Israel.
Marina BrodInternal Medicine F, Sheba Medical Center, Ramat-Gan, Israel.
Anat Wieder-FinesodFaculty of Medical and Health Sciences, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel.
Eyal LeshemFaculty of Medical and Health Sciences, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel.
Erez MagielDepartment of Neurology, Sheba Medical Center, Ramat-Gan, Israel.
Itzchak LevyFaculty of Medical and Health Sciences, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel.
Yaniv LustigFaculty of Medical and Health Sciences, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel.
Victoria IndenbaumFaculty of Medical and Health Sciences, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel.
Nicola MaggioFaculty of Medical and Health Sciences, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel.
Shahar DekelInternal Medicine D, Sheba Medical Center, Ramat-Gan, Israel.
Bella MechnikInfectious Control Unit, Sheba Medical Center, Ramat-Gan, Israel.
Yovel PeretzInfectious Control Unit, Sheba Medical Center, Ramat-Gan, Israel.
Noam BardaThe Sheba Pandemic Preparedness Research Institute (SPRI), Sheba Medical Center, Ramat-Gan, Israel.
Amir TafeshInfectious Diseases Division, Rambam Health Care Campus, Haifa, Israel.
Dafna Yahav *Faculty of Medical and Health Sciences, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel.
Gili Regev-Yochay *Faculty of Medical and Health Sciences, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSince May 2024, Israel has been experiencing a large West Nile virus (WNV) outbreak. We aimed to compare the clinical characteristics and outcomes of hospitalized cases to previous years and identify predictors of poor outcomes.

methodsA retrospective study. We compared WNV infection cases hospitalized during the 2024 outbreak (from 29 May to 29 July) to cases hospitalized during 2018-2023. For the entire cohort, risk factors for poor outcomes were investigated using multivariable analyses. The primary outcomes were death and a composite outcome of 30-day all-cause mortality, prolonged hospitalization (≥ 28 days), or discharge to an institution.

resultsWe included 134 patients, 103 admitted during 2024 and 31 during 2018-2023. The majority (109/134, 81%) had neuroinvasive disease, mostly encephalitis. In 2024, patients were older, with a lower functional state, and a higher proportion were severely immunocompromised. Mortality was numerically higher in 2024 (15/103, 15% versus 2/31, 6%). Altogether, nearly 40% of patients had poor outcomes, including 13% (17/134) mortality and 25% (34/134) discharged to institutions. Nearly 30% of patients who were severely immunocompromised died; all had B-cell depletion. Age was the only significant predictor of poor outcomes in multivariable analysis; however, patients with B-cell depletion had > 3 times higher odds for mortality (odds ratio 3.26, 95% confidence interval 0.73-13.07).

conclusionsThe large 2024 outbreak of WNV was associated with considerable mortality and functional impairment among hospitalized patients that was higher compared with previous years. Poor outcomes were particularly observed in older adults and patients with B-cell depletion. The observation of severe disease and poor outcomes in patients with B-cell depletion, as well as possible therapeutic implications, should be further investigated.

Indexed as

IsraelMortalityNeuroinvasive diseaseOutbreakWest Nile virus

Identifiers

PMID40180788
PMCPMC12271017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.